POS-112 EFFECT OF AVACOPAN, A SELECTIVE C5A RECEPTOR INHIBITOR, ON COMPLEMENT 3 GLOMERULOPATHY HISTOLOGIC INDEX OF DISEASE CHRONICITY

Abstract

Complement 3 Glomerulopathy (C3G) is a rare kidney disorder comprising C3 Glomerulonephritis and Dense Deposit Disease. C3G is caused by dysregulation of the alternative complement pathway, often leading to increased levels of terminal fragments of C5 pathway, including C5a. C3G patients can present with proteinuria, hematuria, renal insufficiency, and/or hypertension, and commonly experience end-stage renal disease (ESRD) within 10 years after diagnosis.